Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma acquisition news. Dermira, which is being acquired for $18.75 per share, has been engaged in developing dermatology products for the […]
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]
Continue reading …AMZEEQ FDA approval : Israeli specialty pharma company Foamix Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for AMZEEQ (minocycline) topical foam, 4% for the treatment of moderate to severe acne. Previously known as FMX101, AMZEEQ has been indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne […]
Continue reading …Castle Creek acquisition of Fibrocell : Castle Creek Pharmaceutical Holdings (CCP Holdings) has agreed to acquire Fibrocell Science, a cell and gene therapy company engaged in developing autologous cell-based therapies for skin and connective tissue disorders. Financial terms of the deal were not disclosed, as per the latest pharma industry news. CCP Holdings is a […]
Continue reading …X-Chem, a US biotech company, has entered into a drug discovery partnership with Japanese dermatology company Maruho to discover lead compounds for new and difficult targets for the treatment of human ailments. Post agreement, X-Chem will use its DNA-encoded library (DEX) screening platform to search for novel drug-like leads for Maruho targets associated with human […]
Continue reading …Researchers in the US have developed a new skin patch as a potentially new melanoma treatment by delivering medication to cancer cells in one minute. Microneedle patch, which could be used to deliver vaccines to combat different infectious diseases, was tested in mice and human skin samples. Melanoma, a form of skin cancer, has been […]
Continue reading …Israeli pharma company Foamix Pharmaceuticals has filed a new drug application (NDA) for FMX103 to the US Food and Drug Administration (FDA) seeking FMX103 FDA approval for moderate-to-severe papulopustular rosacea in patients, aged 18 years and over. Considered to be a common skin condition, rosacea results in redness and visible blood vessels in the face. […]
Continue reading …BridgeBio Pharma, a clinical-stage biopharma company focused on the development of drugs for genetic diseases, raised $299.2 million in a new funding round. The California-based biopharma company said that it will utilize the proceeds from the funding round to support its ongoing drug and research and development programs and expand its efforts to accelerate development […]
Continue reading …Spanish pharma company Almirall has completed its $550 million acquisition of five skin medications from Allergan’s Medical Dermatology unit in the US. The skin medications acquired by Almirall, as part of a deal signed in August 2018, are acne and dermatoses brands Aczone (dapsone), Tazorac (tazarotene), Cordran Tape (flurandrenolide), Azelex (azelaic acid). Along with them, […]
Continue reading …Pharma acquisition news : Sandoz US, a subsidiary of Swiss pharma company Novartis, has agreed to sell its dermatology and oral solids businesses to Indian pharma company Aurobindo Pharma in a deal that could fetch it up to $1 billion. As per the terms of the deal, the Indian pharma company through its subsidiary Aurobindo […]
Continue reading …